Moomoo AI 已提取核心信息
Intelligent Bio Solutions Inc. (INBS), a medical technology company, has successfully regained compliance with two critical Nasdaq Listing Rules, as per the announcements made on February 16, 2024. The company had previously been notified of non-compliance due to its common stock bid price falling below the $1.00 minimum requirement and its stockholders' equity being below the Nasdaq Capital Market's minimum. However, after the closing bid price of INBS's common stock remained at $1.00 or higher for 11 consecutive business days, from January 29 to February 12, 2024, Nasdaq confirmed the company's compliance with the Minimum Bid Price Requirement. Additionally, a compliance plan submitted by INBS, which included a pro forma balance sheet showing stockholders' equity of $4,240,629 as of October 31, 2023, led to Nasdaq confirming the company's compliance with the Stockholders' Equity Requirement upon filing its Quarterly Report for the period ended December 31, 2023. These developments have resulted in Nasdaq considering the matter closed, and INBS issued a press release to report its regained compliance.
Intelligent Bio Solutions Inc. (INBS), a medical technology company, has successfully regained compliance with two critical Nasdaq Listing Rules, as per the announcements made on February 16, 2024. The company had previously been notified of non-compliance due to its common stock bid price falling below the $1.00 minimum requirement and its stockholders' equity being below the Nasdaq Capital Market's minimum. However, after the closing bid price of INBS's common stock remained at $1.00 or higher for 11 consecutive business days, from January 29 to February 12, 2024, Nasdaq confirmed the company's compliance with the Minimum Bid Price Requirement. Additionally, a compliance plan submitted by INBS, which included a pro forma balance sheet showing stockholders' equity of $4,240,629 as of October 31, 2023, led to Nasdaq confirming the company's compliance with the Stockholders' Equity Requirement upon filing its Quarterly Report for the period ended December 31, 2023. These developments have resulted in Nasdaq considering the matter closed, and INBS issued a press release to report its regained compliance.
根据2024年2月16日发布的公告，医疗技术公司智能生物解决方案公司（INBS）已成功恢复对两项重要的纳斯达克上市规则的遵守。该公司此前曾收到违规通知，原因是其普通股出价低于1.00美元的最低要求，其股东权益低于纳斯达克资本市场的最低水平。但是，在2024年1月29日至2月12日连续11个工作日INBS普通股的收盘价保持在1.00美元或更高之后，纳斯达克确认该公司遵守了最低出价要求。此外，INBS提交的合规计划包括一份预计资产负债表，显示截至2023年10月31日的股东权益为4,240,629美元，这促使纳斯达克在提交截至2023年12月31日的季度报告时确认该公司遵守了股东权益要求。这些事态发展导致纳斯达克认为此事已结案，INBS发布了一份新闻稿，报告其恢复了合规性。
根据2024年2月16日发布的公告，医疗技术公司智能生物解决方案公司（INBS）已成功恢复对两项重要的纳斯达克上市规则的遵守。该公司此前曾收到违规通知，原因是其普通股出价低于1.00美元的最低要求，其股东权益低于纳斯达克资本市场的最低水平。但是，在2024年1月29日至2月12日连续11个工作日INBS普通股的收盘价保持在1.00美元或更高之后，纳斯达克确认该公司遵守了最低出价要求。此外，INBS提交的合规计划包括一份预计资产负债表，显示截至2023年10月31日的股东权益为4,240,629美元，这促使纳斯达克在提交截至2023年12月31日的季度报告时确认该公司遵守了股东权益要求。这些事态发展导致纳斯达克认为此事已结案，INBS发布了一份新闻稿，报告其恢复了合规性。
有用
没用